These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. Kollins SH J Clin Psychiatry; 2003; 64 Suppl 11():14-8. PubMed ID: 14529325 [TBL] [Abstract][Full Text] [Related]
9. [The medical treatment of attention deficit hyperactivity disorder (ADHD) with amphetamines in children and adolescents]. Frölich J; Banaschewski T; Spanagel R; Döpfner M; Lehmkuhl G Z Kinder Jugendpsychiatr Psychother; 2012 Sep; 40(5):287-99; quiz 299-300. PubMed ID: 22869222 [TBL] [Abstract][Full Text] [Related]
10. A review of studies of drug treatment efficacy for attention deficit disorder with hyperactivity in adolescents. Varley CK Psychopharmacol Bull; 1985; 21(2):216-21. PubMed ID: 2860692 [No Abstract] [Full Text] [Related]
11. Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature. Kraemer M; Uekermann J; Wiltfang J; Kis B Clin Neuropharmacol; 2010 Jul; 33(4):204-6. PubMed ID: 20571380 [TBL] [Abstract][Full Text] [Related]
12. Methylphenidate versus dextroamphetamine in ADHD. Efron D J Am Acad Child Adolesc Psychiatry; 1999 May; 38(5):500. PubMed ID: 10230180 [No Abstract] [Full Text] [Related]
13. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006. Harpin VA Arch Dis Child Educ Pract Ed; 2008 Apr; 93(2):58-65. PubMed ID: 18356307 [TBL] [Abstract][Full Text] [Related]
14. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Leonard BE; McCartan D; White J; King DJ Hum Psychopharmacol; 2004 Apr; 19(3):151-80. PubMed ID: 15079851 [No Abstract] [Full Text] [Related]
15. [Attention deficit-hyperactivity disorder (ADHD); etiology, diagnosis and treatment]. 't Jong GW; van den Anker JN Ned Tijdschr Geneeskd; 2000 Nov; 144(46):2227-8. PubMed ID: 11103263 [No Abstract] [Full Text] [Related]
16. [Central nervous system stimulants and their potential risk of abuse in hyperkinetic disorders]. Aanonsen NO Tidsskr Nor Laegeforen; 1999 Nov; 119(27):4040-2. PubMed ID: 10613094 [TBL] [Abstract][Full Text] [Related]
17. Stimulant medication withdrawal during long-term therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Nolan EE; Gadow KD; Sprafkin J Pediatrics; 1999 Apr; 103(4 Pt 1):730-7. PubMed ID: 10103294 [TBL] [Abstract][Full Text] [Related]
18. Methylphenidate for attention-deficit/hyperactivity disorder: The longest debate. Levy F Aust N Z J Psychiatry; 2016 Jul; 50(7):616-7. PubMed ID: 27066820 [No Abstract] [Full Text] [Related]
19. Comments on efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder. Pae CU Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1149-50; author reply 1151-2. PubMed ID: 17493730 [No Abstract] [Full Text] [Related]
20. Attention deficit hyperactivity disorder: part III. Ryan-Krause P J Pediatr Health Care; 2011; 25(1):50-6. PubMed ID: 21147408 [No Abstract] [Full Text] [Related] [Next] [New Search]